Briefing
MolDX lists breast-cancer MRD coverage for neoadjuvant disease and for recurrence in advanced disease
The MolDX billing article A58434, in the revision effective January 1, 2026, lists Signatera for neoadjuvant breast cancer and lists NeXT Personal, Pathlight, RaDaR, and Signatera for recurrence or relapse testing in advanced breast cancer.